Harper J L, Gill J C, Hopp R J, Evans J, Haire W D
Department of Pediatrics, University of Nebraska College of Medicine, Omaha, USA.
Thromb Haemost. 1995 Oct;74(4):1039-41.
Anaphylactic reactions were a rare complication of low purity VIII concentrates, but not with high purity VIII concentrates.
7 y/o WM with severe hemophilia A, received only cryoprecipitate and monoclonally purified VIII concentrates; developed post-infusional urticaria. A 2-Bethesda-unit inhibitor was detected. Generalized urticaria and bronchospasm following factor developed as the titer increased. Skin tests demonstrated reactivity to plasma derived VIII, but not recombinant VIII (rhVIII). Attempts at desensitization using rhVIII failed. ELISA revealed an anti-VIII IgE antibody. He was treated with a modified tolerance regimen using rhVIII starting at 500 U/day with aggressive premedication. The dosage increased by 200 U weekly as tolerated to a maximum of 100 U/kg/d without symptoms.
His antibody titer decreased rapidly once he started 100 U/kg/d. Six months later, the inhibitor was < 1 Bethesda unit.
Immune tolerance induction using a graduated dosage of rhVIII was successful.
过敏反应是低纯度VIII因子浓缩剂的一种罕见并发症,但高纯度VIII因子浓缩剂不会引发此类反应。
一名7岁重度甲型血友病男性患儿,此前仅接受冷沉淀和单克隆纯化VIII因子浓缩剂治疗,输注后出现荨麻疹。检测到2个贝塞斯达单位的抑制剂。随着抑制剂滴度升高,输注因子后出现全身性荨麻疹和支气管痉挛。皮肤试验显示对血浆源性VIII因子有反应,但对重组VIII因子(rhVIII)无反应。使用rhVIII进行脱敏治疗失败。酶联免疫吸附测定显示存在抗VIII因子IgE抗体。对其采用改良的耐受方案进行治疗,起始剂量为每天500单位rhVIII,并进行积极的预处理。剂量每周增加200单位,最大耐受剂量为100单位/千克/天,且未出现症状。
一旦开始以100单位/千克/天的剂量治疗,其抗体滴度迅速下降。6个月后,抑制剂水平降至<1个贝塞斯达单位。
使用逐步递增剂量的rhVIII诱导免疫耐受是成功的。